SEC Filing Summary: Lifecore Biomedical, Inc. (LFCR)
Business Context and Reporting Period
This Form 8-K Current Report, dated January 2, 2025, announces the consolidated financial results for the fiscal quarter ended November 24, 2024. The filing serves to disseminate a press release and investor presentation materials to the public.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being contained within the attached press release (Exhibit 99.1) and investor presentation (Exhibit 99.2), which are not included in the source text.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. Investors must refer to the attached exhibits for comparative financial analysis.
Guidance, Outlook, and Risks
Management commentary, forward-looking guidance, and risk factors are detailed in the Investor Presentation (Exhibit 99.2) and the Press Release (Exhibit 99.1). The filing explicitly states that the information in these exhibits is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, nor is it incorporated by reference into other filings unless expressly stated.
Key Facts for Investor Verification
- Verify the specific revenue and net income figures for the quarter ended November 24, 2024, in the attached Press Release (Exhibit 99.1).
- Review the Investor Presentation (Exhibit 99.2) for updated guidance and strategic outlook.
- Note that the financial data in this 8-K is furnished but not "filed" under Section 18 of the Exchange Act, limiting liability protections for the Company regarding these specific disclosures.
- Confirm the fiscal quarter end date of November 24, 2024, aligns with the Company's 52-53 week fiscal year structure.